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A B S T R A C T
Background
Tinnitus is the perception of sound without external acoustic stimuli. Patients with severe tinnitus may have physical and psychological
complaints and their tinnitus can cause deterioration in their quality of life. At present no specific therapy for tinnitus has been found to
be satisfactory in all patients. In recent decades, a number of reports have suggested that oral zinc supplementation may be effective in
the management of tinnitus. Since zinc has a role in cochlear physiology and in the synapses of the auditory system, there is a plausible
mechanism of action for this treatment.
Objectives
To evaluate the effectiveness and safety of oral zinc supplementation in the management of patients with tinnitus.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL
2016, Issue 6); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and
unpublished trials. The date of the search was 14 July 2016.
Selection criteria
Randomised controlled trials comparing zinc supplementation versus placebo in adults (18 years and over) with tinnitus.
Data collection and analysis
We used the standard methodological procedures recommended by Cochrane. Our primary outcome measures were improvement
in tinnitus severity and disability, measured by a validated tinnitus-specific questionnaire, and adverse effects. Secondary outcomes
were quality of life, change in socioeconomic impact associated with work, change in anxiety and depression disorders, change in
psychoacoustic parameters, change in tinnitus loudness, change in overall severity of tinnitus and change in thresholds on pure tone
audiometry. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included three trials involving a total of 209 participants. The studies were at moderate to high risk of bias. All included studies had
differences in participant selection criteria, length of follow-up and outcome measurement, precluding a meta-analysis. The participants
were all adults over 18 years with subjective tinnitus, but one study conducted in 2013 (n = 109) included only elderly patients.
Improvement in tinnitus severity and disability
Only the study in elderly patients used a validated instrument (Tinnitus Handicap Questionnaire) for this primary outcome. The
authors of this cross-over study did not report the results of the two phases separately and found no significant differences in the
proportion of patients reporting tinnitus improvement at four months of follow-up: 5% (5/93) versus 2% (2/94) in the zinc and
placebo groups, respectively (risk ratio (RR) 2.53, 95% confidence interval (CI) 0.50 to 12.70; very low-quality evidence).
None of the included studies reported any significant adverse effects.
Secondary outcomes
For the secondary outcome change in tinnitus loudness, one study reported no significant difference between the zinc and placebo
groups after eight weeks: mean difference in tinnitus loudness -9.71 dB (95% CI -25.53 to 6.11; very low-quality evidence). Another
study also measured tinnitus loudness but used a 0- to 100-point scale. The authors of this second study reported no significant
difference between the zinc and placebo groups after four months: mean difference in tinnitus loudness rating scores 0.50 (95% CI -
5.08 to 6.08; very low-quality evidence).
Two studies used unvalidated instruments to assess tinnitus severity. One (with 50 participants) reported the severity of tinnitus using
a non-validated scale (0 to 7 points) and found no significant difference in subjective tinnitus scores between the zinc and placebo
groups at the end of eight weeks of follow-up (mean difference (MD) -1.41, 95% CI -2.97 to 0.15; very low-quality evidence). A third
trial (n = 50) also evaluated the improvement of tinnitus using a non-validated instrument (a 0 to 10 scale: 10 = severe and unbearable
tinnitus). In this study, after eight weeks there was no difference in the proportion of patients with improvement in their tinnitus, 8.7%
(2/23) treated with zinc versus 8% (2/25) of those who received a placebo (RR 1.09, 95% CI 0.17 to 7.10, very low-quality evidence).
None of the included studies reported any of our other secondary outcomes (quality of life, change in socioeconomic impact associated
with work, change in anxiety and depression disorders, change in psychoacoustic parameters or change in thresholds on pure tone
audiometry).
Authors’ conclusions
We found no evidence that the use of oral zinc supplementation improves symptoms in adults with tinnitus.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplements for tinnitus
Background
Tinnitus is the perceived sensation of sound in the ear or head. Severe tinnitus affects 1% to 2% of the population. People with severe
tinnitus frequently have psychological changes and a decrease in their quality of life. Tinnitus is difficult to control and many doctors
are testing new treatments to improve the quality of life of people who suffer from this problem. This review looked for high-quality
studies in the literature that involved zinc supplements as a possible treatment for tinnitus in adults. The aim was to evaluate whether
oral zinc is effective in the treatment of tinnitus.
Study characteristics
We included a total of three trials involving 209 participants who were treated with oral zinc pills or placebo. All patients were adults
over 18 years who had subjective tinnitus. All three studies investigated improvement in tinnitus as their primary outcome. One study
assessed adverse effects and our secondary outcome ’change in overall severity of tinnitus’. Two studies assessed tinnitus loudness. Only
one study, which enrolled only elderly patients, used a validated instrument (the Tinnitus Handicap Questionnaire (THQ)) to measure
the primary outcome. The other two studies measured tinnitus using scales (from 0 to 7 and from 0 to 10), but these scales were not
validated instruments for studying tinnitus.
Key results
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All three included studies had differences in their participant selection, length of follow-up and outcome measurement, which prevented
a meta-analysis (combining of results).
Only one trial (conducted in 2013) used a validated instrument (the THQ) to measure improvement in tinnitus, our primary outcome.
The authors reported no significant difference between the groups. Another study (2003) reported the severity of tinnitus using a non-
validated scale (0 to 7) and found a significant difference in the subjective tinnitus scores, which favoured the zinc group. However,
this result may be biased because the losses were unbalanced and higher in the placebo group. A third study (1991) also evaluated
improvement of tinnitus using a non-validated instrument (a scale of 0 to 10) and found no significant difference between groups.
There were no severe adverse effects associated with zinc. Three cases of mild adverse effects were reported in different participants (e.g.
mild gastric symptoms).
Two studies (2003 and 2013) assessed change in tinnitus loudness (one of our secondary outcomes), but did not find a difference
between patients treated with zinc compared to those who took a placebo.
Two studies assessed change in the overall severity of tinnitus. One study, published in 1991, did not find any difference for this
outcome between the groups. The second study, published in 2003, reported a significant reduction in subjective tinnitus score in the
zinc group and no difference in the placebo group. However, both studies used a non-validated scale.
Quality of the evidence
The quality of the evidence is very low. We found no evidence that the use of oral zinc supplementation improves symptoms in adults
with tinnitus. This evidence is up to date to 14 July 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Zinc supplementation compared with placebo for tinnitus
Patient or population: adults over 18 years with t innitus
Settings: outpat ient clinics in universit ies
Intervention: zinc supplementat ion
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Zinc
Improvement in t inni-
tus severity and disabil-
ity, measured by a val-
idated t innitus-specif ic
quest ionnaire (THQ)
Proport ion of pat ients
improved
4 months
Medium risk populat ion 2.53 (0.50 to 12.70) 187 part icipants (1
study)
⊕©©©
very low 1,2,3
-
21 per 1000 53 per 1000
(10 to 267)
Adverse ef fects of
treatment
Not reported Not reported Not reported Not reported - -
Quality of lif e Not reported Not reported Not reported Not reported - -
Socioeconomic impact
associated with work
Not reported Not reported Not reported Not reported - -
Anxiety and depression
disorders
Not reported Not reported Not reported Not reported - -
Psychoacoust ic param-
eters
Not reported Not reported Not reported Not reported - -
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Tinnitus loudness (dB)
8 weeks
0 to 100 scale
4 months
- - MD -9.71
(-25.53 to 6.11)
MD 0.50
(-6.58 to 7.58)
41
(1)
116
(1)
⊕©©©
very low 1,2,3
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io; THQ: Tinnitus Handicap Quest ionnaire
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level due to publicat ion bias because few studies were ident if ied.
2Downgraded one level due to risk of select ion bias (unclear randomisat ion method).
3Downgraded one level due to imprecision because the sample size was small.
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B A C K G R O U N D
The following paragraphs and Description of the condition are
based on theCochraneReview ’Amplificationwith hearing aids for
patients with tinnitus and co-existing hearing loss’ and reproduced
with permission (Hoare 2014).
Tinnitus is defined as the perception of sound in the absence of
an external source (Jastreboff 2004). It is typically described by
those who experience it as a ringing, hissing, buzzing or whooshing
sound and is thought to result from abnormal neural activity at
some point or points in the auditory pathway, which is erroneously
interpreted by the brain as sound. Tinnitus can be either objective
or subjective. Objective tinnitus refers to the perception of sound
that can also be heard by the examiner and is usually due to blood
flow or muscle movement (Eggermont 2010). Most commonly,
however, tinnitus is subjective; the sound is only heard by the
person experiencing it and no source of the sound is identified
(Jastreboff 1988).
Subjective tinnitus affects 10% of the general population, increas-
ing to as many as 30% of adults over the age of 50 years (Davis
2000; Møller 2000). It can be experienced acutely, recovering
spontaneously within minutes to weeks, but is considered chronic
and unlikely to resolve spontaneously when experienced for three
months or more (Hahn 2008; Hall 2011; Rief 2005).
In England alone there are an estimated ¾ million general prac-
titioner (GP) consultations every year where the primary com-
plaint is tinnitus (El-Shunnar 2011), equating to a major burden
on healthcare services. For many people tinnitus is persistent and
troublesome, and has disabling effects such as insomnia, difficulty
concentrating, difficulties in communication and social interac-
tion, and negative emotional responses such as anxiety and de-
pression (Andersson 2009; Crönlein 2007; Marciano 2003). In
approximately 90% of cases, chronic tinnitus is co-morbid with
some degree of hearing loss, which may confound these disabling
effects (Fowler 1944; Sanchez 2002). An important implication of
this in clinical research, therefore, is that outcome measures need
to distinguish benefits specific to improved hearing from those
specific to tinnitus.
Description of the condition
Diagnosis and clinical management of tinnitus
There is no standard procedure for the diagnosis ormanagement of
tinnitus. Practice guidelines and the approaches described in stud-
ies of usual clinical practice typically reflect differences between
the clinical specialisms of the authors or differences in the clinical
specialisms charged with meeting tinnitus patients’ needs (medi-
cal, audiology/hearing therapy, clinical psychology, psychiatry), or
the available resources of a particular country or region (access to
clinicians or devices, for example) (Biesinger 2011; Cima 2012;
Department of Health 2009; Hall 2011; Henry 2008; Hoare
2011a). Common across all these documents, however, is the use
or recommendation of written questionnaires to assess tinnitus
and its impact on patients by measuring severity, quality of life,
depression or anxiety. Psychoacoustic measures of tinnitus (pitch,
loudness, minimum masking level) are also recommended. Al-
though these measures do not correlate well with tinnitus severity
(Hiller 2006), they can prove useful in patient counselling (Henry
2004), or by demonstrating stability of the tinnitus percept over
time (Department of Health 2009).
Clinical management strategies include education and advice, re-
laxation therapy, tinnitus retraining therapy (TRT), cognitive be-
havioural therapy (CBT), sound enrichment using ear-level sound
generators or hearing aids, and drug therapies to manage co-mor-
bid symptoms such as insomnia, anxiety or depression. The ef-
fects of these management options are variable and they have few
known risks or adverse effects (Dobie 1999; Hoare 2011; Hobson
2012; Martinez-Devesa 2010; Phillips 2010).
Pathophysiology
Most people with chronic tinnitus have some degree of hearing
loss (Ratnayake 2009), and the prevalence of tinnitus increases
with greater hearing loss (Han 2009;Martines 2010). The varying
theories of tinnitus generation involve changes in either function
or activity of the peripheral (cochlea and auditory nerve) or central
auditory nervous systems (Henry 2005). Theories involving the
peripheral systems include the discordant damage theory, which
predicts that the loss of outer hair cell function, where inner hair
cell function is left intact, leads to a release from inhibition of inner
hair cells and aberrant activity (typically hyperactivity) in the au-
ditory nerve (Jastreboff 1990). Such aberrant auditory nerve activ-
ity can also have a biochemical basis, resulting from excitotoxicity
or stress-induced enhancement of inner hair cell glutamate release
with up-regulation of N-methyl-D-aspartate (NMDA) receptors
(Guitton 2003; Sahley 2001).
In the central auditory system, structures implicated as possible
sites of tinnitus generation include the dorsal cochlear nucleus
(Middleton 2011; Pilati 2012), the inferior colliculus (Dong 2010;
Mulders 2010), and the auditory and non-auditory cortex (dis-
cussed further below). There is a strong rationale that tinnitus
is a direct consequence of maladaptive neuroplastic responses to
hearing loss (Møller 2000;Mühlnickel 1998). This process is trig-
gered by sensory deafferentation and a release from lateral inhi-
bition in the central auditory system allowing irregular sponta-
neous hyperactivity within the central neuronal networks involved
in sound processing (Eggermont 2004; Rauschecker 1999; Seki
2003). As a consequence of this hyperactivity, a further physio-
logical change noted in tinnitus patients is increased spontaneous
synchronous activity occurring at the cortical level, measurable us-
ing electroencephalography (EEG) or magnetoencephalography
(MEG) (Dietrich 2001; Tass 2012; Weisz 2005). Another physi-
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ological change thought to be involved in tinnitus generation is a
process of functional reorganisation, which amounts to a change
in the response properties of neurons within the primary auditory
cortex to external sounds. This effect is well demonstrated physio-
logically in animal models of hearing loss (Engineer 2011; Noreña
2005). Evidence in humans, however, is limited to behavioural
evidence of cortical reorganisation after hearing loss, demonstrat-
ing improved frequency discrimination ability at the audiomet-
ric edge (Kluk 2006; McDermott 1998; Moore 2009; Thai-Van
2002; Thai-Van 2003), although Buss 1998 did not find this ef-
fect. For comprehensive reviews of these physiological models, see
Adjamian 2009 and Noreña 2005.
It is also proposed that spontaneous hyperactivity could cause an
increase in sensitivity or ’gain’ at the level of the cortex, whereby
neural sensitivity adapts to the reduced sensory inputs, in effect
stabilising mean firing and neural coding efficiency (Noreña 2011;
Schaette 2006; Schaette 2011). Such adaptive changes would be
achieved at the cost of amplifying ’neural noise’ due to the overall
increase in sensitivity, ultimately resulting in the generation of
tinnitus.
Increasingly, non-auditory areas of the brain, particularly areas as-
sociated with emotional processing, are also implicated in bother-
some tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste 2012
describes tinnitus as “an emergent property of multiple parallel
dynamically changing and partially overlapping sub-networks”,
implicating the involvement of many structures of the brain more
associated withmemory and emotional processing in tinnitus gen-
eration. However, identification of the structural components of
individual neural networks responsible for either tinnitus genera-
tion or tinnitus intrusiveness, which are independent of those for
hearing loss, remains open to future research (Melcher 2013).
One further complication in understanding the pathophysiology
of tinnitus is that not all people with hearing loss have tinnitus and
not all people with tinnitus have a clinically significant hearing
loss. Other variables, such as the profile of a person’s hearing loss,
may account for differences in their tinnitus report. For example,
König 2006 found that the maximum slope within audiograms
was higher in people with tinnitus than in people with hearing loss
who do not have tinnitus, despite the ’non-tinnitus’ group having
the greater mean hearing loss. This suggests that a contrast in
sensory inputs between regions of normal and elevated threshold
may be more likely to result in tinnitus.
The intensity and consequences of tinnitus may be measured in
different ways (see Appendix 1; ’Tinnitus measurement tools’).
Description of the intervention
Zinc is an important oligoelement involved in several physiological
functions including central neurotransmission (Gersdorff 1987).
Copper/zinc superoxide dismutase (Cu/Zn SOD) is a first-line
defence against free radical damage in the cochlea (MacFadden
1999). Zinc is involved in several other important physiological
systems, such as the Na-K-ATPase pump. Deficiency of this trace
element can modify endocochlear potentials, affect cochlear elec-
trophysiology and generate tinnitus. In 1987, Gersdorff hypothe-
sised that altered zinc physiology could be related to tinnitus gen-
eration (Gersdorff 1987), and in 1991 the systemic administration
of zinc was tested as an alternative treatment for this condition
(Paaske 1991). The existence of a correlation between progressive
sensorineural hearing loss, similar to presbyacusis, tinnitus and
serum hypozincaemia has been suggested (Shambaugh 1985).
Zinc is absorbed in the small intestine, especially in the jejunum
and ileum, but it is still unclear how it enters into cochlear cells.
Some authors have suggested, based on their clinical practice, that
some patients have improvement of their tinnitus with oral ad-
ministration of zinc compounds, especially elderly people (Person
2004; Shambaugh 1986). The assessment of serological zinc levels
before metal replacement therapy is not recommended because
clinical improvement of tinnitus has been observed in patients
with low, normal or elevated zinc levels (Person 2004).
How the intervention might work
Glutamate is the presumed neurotransmitter in inner hair cells
(Drescher 1992) and central auditory pathways (Person 2004).
Abnormalities in synaptic transmission between these cells and the
cochlear nerve could increase the spontaneous activity of neural fi-
bres, generating tinnitus (Jastreboff 1990). Zinc, an oligoelement
present in the auditory system, is involved in glutamatergic exci-
tation of synaptic networks. This metal seems to act on the post-
synaptic receptors of some glutamatergic synapses (Frederickson
2000). Thus, by modulating glutamatergic action in the central
auditory pathways, zinc could modify tinnitus and reduce the
perception of this symptom in some patients. Additionally, the
cochlear antioxidant effects of zinc could also be related to the
improvement of tinnitus in some patients (Person 2010).
Why it is important to do this review
Zinc deficiency increases with advancing age, especially after the
age of 60, and this could be a factor that predisposes to tinnitus
(Shambaugh 1986). Abnormal zinc physiology has been associ-
ated with the onset of tinnitus. Systematic administration of zinc
has therefore been tested as an alternative treatment for this disor-
der by several investigators over recent decades (Gersdorff 1987;
Person 2004). However, to date there has been no systematic as-
sessment of these studies. This review is important because it crit-
ically appraises and synthesises the best available evidence on the
efficacy of zinc supplementation in the treatment of tinnitus in
adults. This information could be useful for optimising the treat-
ment of these patients and potentially reducing costs.
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O B J E C T I V E S
To evaluate the effectiveness and safety of oral zinc supplementa-
tion in the management of patients with tinnitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (including those with a cross-over
design).
Types of participants
Adults over 18 years.
Types of interventions
Oral zinc supplementation alone, in any dose or frequency, versus
placebo, for the treatment of tinnitus.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Improvement in tinnitus severity and disability, measured
by a validated tinnitus-specific questionnaire (Appendix 1).
• Adverse effects of treatment with oral zinc supplementation.
Secondary outcomes
• Quality of life.
• Change in socioeconomic impact associated with work.
• Change in anxiety and depression disorders.
• Change in psychoacoustic parameters.
• Change in tinnitus loudness.
• Change in overall severity of tinnitus.
• Change in thresholds on pure tone audiometry.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 14 July 2016.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Trials Register (searched 14 July 2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 6);
• PubMed (1946 to 14 July 2016);
• Ovid EMBASE (1974 to 14 July 2016);
• Ovid CAB Abstracts (1910 to 14 July 2016);
• EBSCO CINAHL (1982 to 14 July 2016);
• Ovid AMED (1985 to 14 July 2016);
• LILACS, lilacs.bvsalud.org (searched 14 July 2016);
• KoreaMed (searched via Google Scholar 14 July 2016);
• IndMed, www.indmed.nic.in (searched 14 July 2016);
• PakMediNet, www.pakmedinet.com (searched 14 July
2016);
• Web of Knowledge, Web of Science (1945 to 14 July 2016);
• CNKI, www.cnki.com.cn (searched via Google Scholar 14
July 2016);
• ClinicalTrials.gov (searched via the Cochrane Register of
Studies 14 July 2016);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
14 July 2016);
• ISRCTN, www.isrctn.com (searched 14 July 2016);
• Google Scholar, scholar.google.co.uk (searched 14 July
2016);
• Google, www.google.com (searched 14 July 2016).
In searches prior to 2013, we also searched BIOSIS Previews 1926
to May 2012.
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 2.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, TRIPdatabase,
The Cochrane Library and Google to retrieve existing systematic
reviews relevant to this systematic review, so that we could scan
their reference lists for additional trials.
Data collection and analysis
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Selection of studies
Two authors (OCP and MRT) independently screened the ci-
tations identified and selected those judged possibly relevant by
both for full-text reading. In case of disagreement or uncertainty
of study relevance based on title and abstract screening, we also
retrieved the full-text article. The two independent review authors
read each full paper and assessed each for possible inclusion ac-
cording to the selection criteria. In case of disagreement, we con-
sulted a third senior review author (EMKS). We listed the reasons
for exclusion of all publications selected for full-text reading.
Data extraction and management
Two independent authors (OCP and MRT) extracted the data.
We discussed discrepancies until consensus was reached or with
the help of a third author (EMKS). We used a standard form
created for this review to extract the following information from
each included study:
• characteristics of the study (design, methods of
randomisation and information for ’Risk of bias’ assessment);
• characteristics of participants (including age, gender,
eligibility and exclusion criteria, and baseline characteristics);
• details intervention and comparator;
• outcomes (types of outcome measures, timing of outcome
measurement, adverse events);
• funding sources;
• declarations of interest.
If needed, we contacted the authors to obtain further details.
Assessment of risk of bias in included studies
Two authors (OCP and MRT) independently assessed the in-
cluded studies for risk of bias. We resolved any disagreement
through discussion. As recommended by the Cochrane Handbook
for Systematic Reviews of Interventions, we evaluated the following
items (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting;
• other sources of bias.
We used the Cochrane ’Risk of bias’ tool in RevMan 5.3 (RevMan
2014), which involves describing each of these domains as reported
in the trial and then assigning a judgment about the adequacy of
each entry (low, high or unclear risk of bias).
Measures of treatment effect
For dichotomous variables, we calculated the risk ratio (RR) and
95% confidence interval (CI). For continuous outcomes, we cal-
culated the mean difference (MD) and 95% CI. In the event that
authors did not make available the necessary information, we in-
tended to insert any data from primary studies that were not para-
metric (e.g. effects reported as medians, quartiles, etc.) or without
sufficient statistical information (e.g. standard deviations, number
of patients, etc.) into an additional table.
Unit of analysis issues
The unit of analysis was the individual participant (the unit ran-
domised for interventions to be compared), i.e. the number of
observations in the analysis matched the number of individuals
randomised. For trials with a cross-over design, we would have
included the data using the results of paired analyses (Elbourne
2002).
Dealing with missing data
Irrespective of the type of data, we reported dropout rates in the
Characteristics of included studies table and performed intention-
to-treat analyses.
Assessment of heterogeneity
We quantified inconsistency among the pooled estimates using
the I2 statistic. This illustrates the percentage of the variability in
effect estimates resulting from heterogeneity rather than sampling
error (Deeks 2011; Higgins 2003). The thresholds for the inter-
pretation of I2 were: 0% to 25% low heterogeneity, 25% to 75%
moderate heterogeneity and more than 75% significant hetero-
geneity (Higgins 2003).
Assessment of reporting biases
We intended to assess publication bias by drawing a funnel plot
(trial effect versus trial size), if a sufficient number of studies had
been included in the review.
Data synthesis
For dichotomous variables, we intended to calculate the risk ratio
(also known as the relative risk (RR)). For continuous variables,
we intended to calculate the mean difference (MD) when studies
reported their results using the same variables measured with the
same units of measure. If continuous data were relative to the same
aspect, but were measured with different instruments (different
and not interchangeable units of measure), we would have pooled
these data using the standardised mean difference (SMD). For all
statistical methods, when pooling data we would have reported
the 95% confidence interval (95% CI).
If no significant heterogeneity had been identified, we would have
computed pooled estimates of the treatment effect for each out-
come using a fixed-effect model. If significant heterogeneity had
been identified, we would have performed a random-effects anal-
ysis.
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Subgroup analysis and investigation of heterogeneity
In case of significant heterogeneity, we intended to investigate the
possible causes by exploring the impact of study risk of bias and
the condition of the individuals. If we had identified the sources
of heterogeneity, and if there were sufficient data, we intended to
conduct meta-analyses by subgroups (e.g. by different dosage and
age of participants).
Sensitivity analysis
If the number of studies had been sufficient, we intended to per-
form sensitivity analyses to explore the causes of heterogeneity and
the robustness of the results. We would have included the follow-
ing factors in the sensitivity analyses, grouping studies according
to:
• quality of allocation concealment (adequate or unclear or
inadequate);
• blinding of participants, caregiver and outcome assessment
(adequate or unclear or inadequate or not performed);
• rates of withdrawals for each outcome;
• length of follow-up;
• age of participants.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality of evi-
dence. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high quality of evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of very low quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included a ’Summary of findings’ table (Summary of findings
for the main comparison), constructed according to the recom-
mendations described in Chapter 10 of the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011). We in-
cluded the following outcomes in the ’Summary of findings’ table:
improvement in tinnitus severity and disability (measured by val-
idated scale), change in tinnitus loudness and change in tinnitus
severity (measured by non-validated scale).
R E S U L T S
Description of studies
Results of the search
We ran the searches using the methods set out in the protocol. We
identified 87 records from the searches, but this number dropped
to 56 once duplicates were removed. After closer examination of
the titles and abstracts of these references, we obtained full paper
copies for eight citations that were potentially eligible for inclusion
in the review. Of these eight citations, three studies fulfilled our
inclusion criteria (Arda 2003; Coelho 2013; Paaske 1991). We
excluded five studies (see Characteristics of excluded studies). We
found no ongoing studies and no studies are awaiting assessment.
Figure 1 depicts the search history.
10Zinc supplementation for tinnitus (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Process of study identification and selection.
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Included studies
See Characteristics of included studies.
We included three studies (Arda 2003; Coelho 2013; Paaske
1991).
Design
All studieswere reported to be placebo-controlled and randomised,
but two were unclear in their description of the method of alloca-
tion or sequence generation (Arda 2003; Paaske 1991). One was
described as being a cross-over, double-blind, clinical trial (Coelho
2013). See Risk of bias in included studies.
Sample sizes
A total of 209 participants were included in the three studies,
ranging from 50 to 109 individuals per study, with a mean sample
size of 69. Sample size calculations were rarely reported and this
omission (with probable poor statistical power) was a frequent
methodological flaw.
Setting
All three included studies were conducted in single centres by
otolaryngologists in outpatient clinics in universities.
Participants
All participants were adults over 18 years with subjective tinnitus
and living in the community under normal circumstances who
were recruited in outpatient clinics. Coelho 2013 included 109
participants with a mean age of 67.5 in the zinc group and 67.7
in the placebo group; 66% were male. Arda 2003 included 50
patients with an age range of 21 to 74 years. The mean age was
55 ± 14.3 in the zinc group and 51.2 ± 12.8 in the placebo group.
The zinc group included 16 women (57.1%) and 12men (42.9%)
and the placebo group included nine women (69.2%) and four
men (30.8%). Paaske 1991 included 50 patients between 29 to 77
years of age; the median age in the zinc and placebo groups was 60
and 48 years, respectively. Thirty-one patients (65%) were men.
Interventions
Each trial included two groups of participants: one was treated
with zinc and the other (control group) was given placebo. Coelho
2013 included 109 participants with subjective tinnitus: 54 were
treated with elemental zinc (50 mg for 16 weeks) and 55 received
placebo pills for the same period. After four weeks of washout,
45 patients were treated with zinc and 46 with placebo for 16
weeks. Arda 2003 compared two groups of participants (total 50
patients): 30 were treated with zinc (50 mg daily for eight weeks)
and 20 were given placebo pills for the same period. Paaske 1991
involved a total of 50 patients. Twenty-five received 66 mg of
elemental zinc daily for eight weeks while 25 received a placebo.
Outcomes
The primary outcome measure was the same in all included stud-
ies and involved evaluating the improvement in tinnitus in pa-
tients treated with zinc, but there was considerable variation in
the specific measures used. Coelho 2013 used a validated instru-
ment (Tinnitus Handicap Questionnaire (THQ)), which mea-
sured changes in the score of 20 points or greater to evaluate tin-
nitus. The other two included studies did not use a validated in-
strument. To evaluate improvement of tinnitus Arda 2003 used a
scale where a decrease in tinnitus loudness by at least 10 dB was
accepted as clinically favourable progress. A decrease of more than
one point on a subjective non-validated scale (0 to 7) for tinnitus
was accepted as valid. Paaske 1991 used a scale that evaluated the
severity of tinnitus measured on a scale of 0 to 10.
The secondary outcomes measured were the change in tinnitus
loudness (Arda 2003; Coelho 2013), and adverse effects of oral
zinc treatment (Arda 2003; Coelho 2013). Paaske 1991 did not
evaluate any secondary outcomes.
Excluded studies
We excluded five studies because they were not randomised con-
trolled trials (Gersdorff 1987; Ochi 1997; Ochi 2003; Person
2004; Person 2010). See Characteristics of excluded studies.
Risk of bias in included studies
See the ’Risk of bias’ graph (Figure 2) and ’Risk of bias’ summary
(Figure 3).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
None of the included studies described their method of random
sequence generation, therefore we judged all of them to have an
unclear risk of bias for this domain.
Allocation concealment
One study described how the patients were allocated to each group
by an external department (pharmacy department) and we cat-
egorised it as having a low risk of bias for this domain (Coelho
2013). We judged the other two studies to have an unclear risk
of bias because allocation concealment was not described (Arda
2003; Paaske 1991).
Blinding
The blinding of participants and personnel was described in
Coelho 2013 (low risk of bias). The other two studies did not
describe blinding methods and we therefore judged them to have
an unclear risk of bias for this domain (Arda 2003; Paaske 1991).
Incomplete outcome data
All studies reported withdrawals and dropouts adequately. The
dropout rates for intervention and control groups were low in
the Paaske 1991 study (4%) and moderate in Arda 2003 (18%)
and Coelho 2013 (18%). In Paaske 1991, two participants were
excluded because they did not complete the treatment. In Arda
2003, nine participants (two in the zinc group and seven in the
control group) were non-compliant in taking their pills. In Coelho
2013, 20 patients were excluded because they did not complete
the treatment. The risk of bias was low in the Paaske 1991 and
Coelho 2013 studies and high in the Arda 2003 study.
Selective reporting
We classified all studies as low risk of bias. There was no evidence of
selective reporting in the included studies based on the comparison
of the ’Methods’ with the ’Results’ section in each study, and all
included studies used the primary outcome measure of this review,
improvement of the severity of tinnitus; however, only one study
used a validated instrument. We identified a registration protocol
for only one study (Coelho 2013).
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
The three included studies, Arda 2003, Coelho 2013 and Paaske
1991, differed in their participant selection, length of follow-up
and outcome measurement, precluding meta-analysis. The results
are therefore presented narratively.
See Summary of findings for the main comparison.
Zinc versus placebo
Primary outcomes
Improvement in tinnitus severity and disability, measured by
a validated tinnitus-specific questionnaire
Only the trial conducted by Coelho 2013 used a validated in-
strument (Tinnitus Handicap Questionnaire (THQ)) to measure
improvement in tinnitus. In this cross-over study the authors did
not report the results of the two phases separately, but reported
that 5% of patients (5/93) treated with zinc had improvement in
their tinnitus. In the placebo group, 2% of patients (2/94) had
improvement in their tinnitus at four months of follow-up, with
no significant difference between the groups (risk ratio (RR) 2.53,
95% confidence interval (CI) 0.50 to 12.70, P = 0.26; very low-
quality evidence (Analysis 1.1).
Adverse effects of treatment with oral zinc supplementation
Coelho 2013 reported that adverse effects were mild and only one
participant receiving zinc stopped the trial because of indigestion.
One patient in the placebo group dropped out because of con-
stipation and one because of a metallic taste. Arda 2003 reported
that two patients had mild gastric symptoms. Paaske 1991 stated
that there were no side effects that could be attributed to the in-
tervention.
Secondary outcomes
Quality of life
This outcome was not assessed in the included studies.
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Change in socioeconomic impact associated with work
This outcome was not assessed in the included studies.
Change in anxiety and depression disorders
This outcome was not assessed in the included studies.
Change in psychoacoustic parameters
This outcome was not assessed in the included studies.
Change in tinnitus loudness
Arda 2003 reported no significant differences between the zinc and
placebo group in themean tinnitus loudness after eightweeks: 49.9
(21.97) dB and 59.61 (24.96) dB, respectively (mean difference
(MD) -9.71, 95% CI -25.53 to 6.11, P = 0.23; very low-quality
evidence). Coelho 2013 measured tinnitus loudness on a scale of
0 to 100 after four months and reported no significant difference
between the zinc and placebo group:mean tinnitus loudness rating
scores 68.1 (18.7) and 67.6 (20.2), respectively (MD 0.50, 95%
CI -5.08 to 6.08, P = 0.86; very low-quality evidence) (Analysis
1.2).
Change in overall severity of tinnitus
Arda 2003 reported severity of tinnitus using a non-validated scale
(0 to 7) and found no significant difference in subjective tinnitus
scores between the zinc and placebo groups at the end of eight
weeks of follow-up (MD -1.41, 95% CI -2.97 to 0.15, P = 0.08;
very low-quality evidence) (Analysis 1.3). Paaske 1991 also evalu-
ated improvement of tinnitus using a non-validated instrument (a
scale of 0 to 10, where 0 means no tinnitus and 10 severe and un-
bearable tinnitus). After eight weeks, 8.7% (2/23) of those treated
with zinc and 8% (2/25) of those who received placebo had tinni-
tus improvement, a non-significant difference (RR 1.09, 95% CI
0.17 to 7.10, P = 0.93; very low-quality evidence) (Analysis 1.4).
Change in thresholds on pure tone audiometry
This outcome was not assessed in the included studies.
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
Despite the widespread description of zinc as a potential treatment
for tinnitus, we identified only three studies involving a total of
209 participants for inclusion in this review. These studies had dif-
ferences in participant selection, length of follow-up and outcome
measurement, precluding a meta-analysis. All studies assessed im-
provement in tinnitus as a primary outcome, but only one used
a validated instrument to measure this outcome (Tinnitus Hand-
icap Questionnaire (THQ)) (Coelho 2013). The authors of this
cross-over study did not report the results of the two phases sepa-
rately and they found no significant difference between the groups
at four months of follow-up (very low-quality evidence). A second
study reported the severity of tinnitus using a non-validated 0 to
7 scale and found no significant difference in subjective tinnitus
scoring between the zinc and placebo groups (very low-quality ev-
idence) (Arda 2003). The third study also evaluated tinnitus im-
provement using a non-validated 0 to 10 scale and found a non-
significant difference (very low-quality evidence) (Paaske 1991).
Two studies reported mild adverse effects with zinc supplementa-
tion (Arda 2003; Coelho 2013), while Paaske 1991 did not report
side effects that could be attributed to the intervention.
Change in tinnitus loudness (one of our secondary outcomes) was
measured in different ways in two studies (Arda 2003; Coelho
2013), but there were no significant differences between the zinc
and placebo groups.
Overall completeness and applicability of
evidence
The number of participants included in this review was small and
this is a limiting factor in the assessment of the evidence. Since
there are different causes of tinnitus and clinical manifestation
usually differs between patients, a larger sample size with differ-
ent subgroups of patients with this symptom is needed. It is also
important to distinguish between clinically significant and non-
significant tinnitus, because many patients have tinnitus that has
a non-significant impact in their lives (Davis 2000). Samples also
need to be paired according to audiometric parameters, because
although the majority of patients with tinnitus have hearing loss,
a small subgroup has normal audiometry and this group can have
different behaviour regarding tinnitus loudness.
Although there is a high prevalence of tinnitus worldwide, there
are relatively few studies on this topic, especially in the area of
treatment. In general, these studies look at tinnitus improvement
as their primary outcome while secondary outcomes usually in-
clude quality of life, change in socioeconomic impact, anxiety and
depression disorders and psychoacoustic parameters, while change
in thresholds on pure tone audiometry is seldom assessed. This last
parameter is important because, contrary to the subjective nature
of the other outcomes, it is an objective measure.
This systematic review found no evidence that oral zinc supple-
mentation is effective for the treatment of tinnitus and raised more
questions than answers on this issue.
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Quality of the evidence
The included studies had moderate to high risk of bias. None
adequately described the randomisation process and only one re-
ported concealed allocation and was double-blind. Another study
was unclear about blinding and the third was an open study. The
fact that we only identified three studies that tested zinc supple-
mentation for tinnitus raises the possibility of publication bias.
The small sample size of the studies increases the risk of uncer-
tainty in the estimates. Therefore, we classified the overall quality
of the evidence in this review as very low.
Potential biases in the review process
We conducted a comprehensive search in a wide range of databases
with no language restrictions. To reduce the risk of bias, two in-
dependent authors screened the trials identified by the literature
search and examined the full text of selected studies for compli-
ance with the eligibility criteria. Both authors assessed the risk of
bias of the included studies and extracted data. The authors of
this review were not blinded to the authorship and origin of the
included studies; this could have introduced bias.
All excluded studies were not randomised controlled trials or did
not meet the inclusion criteria. We used all available results in the
included studies that were related to our primary and secondary
outcomes.
We departed from the protocol by including in the review the
results of one of our secondary outcomes (tinnitus severity) mea-
sured by non-validated scales.
Agreements and disagreements with other
studies or reviews
We have not identified any other systematic reviews in the litera-
ture that have assessed zinc for the treatment of tinnitus. However,
there are descriptive studies and experience reports by experts, pri-
marily otolaryngologists, which consider the possible efficacy of
this treatment (Person 2004; Shambaugh 1986). Some authors
and also websites (as cited by Person 2010) have encouraged the
use of zinc to treat tinnitus. Although based on very low-quality
evidence, the findings of this review cannot support the conclu-
sions of these authors and websites.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the claims of many authors that zinc could be an option
for the treatment of tinnitus, there are few studies on this topic.
We found no evidence that the use of oral zinc supplementation
improves symptoms in adults with tinnitus.
Implications for research
Researchers should be encouraged to conduct high-quality studies
to elucidate any potential role of zinc in the treatment of tinni-
tus. Future trials should randomise patients with tinnitus to re-
ceive zinc supplementation or placebo. Validated tinnitus ques-
tionnaires should be used as ameasurement tool before, during and
after treatment and results should be reported for each subgroup
of patients with tinnitus (presence or not of hearing loss; age; oc-
currence or not of limbic recruitment). Patients treated with zinc
should also have an audiological follow-up, because there is some
evidence to indicate that pure tone thresholds can be modified
during treatment (Shambaugh 1986). Outcomes such as quality
of life and socioeconomic impact of the treatment should also be
evaluated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arda 2003
Methods Allocation: randomised, placebo-controlled clinical trial
Design: parallel-group
Participants Number: 50
Age: range 21 to 74 years; mean 55 ± 14.3 (zinc group) and 51.2 ± 12.8 (placebo group)
Gender: zinc group included 16 women (57.1%) and 12 men (42.9%); placebo group
included 9 women (69.2%) and 4 men (30.8%)
Setting: single centre; Ankara, Turkey
Eligibility criteria: the inclusion criteria were that patients had no pathologic conditions
of the ear, nose and throat that might be responsible for tinnitus
Exclusion criteria: not reported
Baseline characteristics: there was no significant difference between the treatment cat-
egory of the tinnitus, or the prevalence of intermittent versus continuous tinnitus, nor
were the mean durations of the tinnitus significantly different between groups
Interventions Intervention group: 50 mg elemental zinc daily for 8 weeks (n = 28)
Comparator group: placebo (n = 13)
Outcomes Primary outcome: improvement of tinnitus: a decrease in tinnitus loudness by at least
10 dB was accepted as clinically favourable progress. A decrease of more than 1 point on
a subjective non-validated scale (0 to 7) for tinnitus was accepted as valid
Funding sources Not reported
Declarations of interest Not reported
Notes Participants lost to follow-up: 2/30 (6.7%) in the zinc group; 7/20 (35.0%) in the
placebo group
8 weeks follow-up
Trials register: not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors did not report the blinding of
participants and personnel
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Arda 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors did not report the blinding of
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses 2/30 (6.7%) and 7/20 (33.8%) in
the zinc group. ITT analysis not performed
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing based on comparison of the methods
and results sections
Other bias Low risk There was no evidence of other bias
Coelho 2013
Methods Allocation: randomised, placebo-controlled, double-blind clinical trial
Design: cross-over
Participants Number: 109
Age: mean age 67.5 (5.4) (zinc group) and 67.7 (5.8) (placebo group)
Gender: 66% male
Setting: single centre, patients attending the tinnitus clinic at the Otolaryngology and
Head and Neck Department at the University of Iowa
Eligibility criteria: 60 years or older, tinnitus duration for 6 months or more, normal
copper levels, generally good health
Exclusion criteria: had a treatable otologic disorder, involved in litigation, presenting
or suspected of having a serious psychiatric problem, involved in other treatments for
tinnitus, taking drugs that might interact with zinc and result in tinnitus, copper defi-
ciency, zinc levels above normal and cognitive impairment
Baseline characteristics: treatment groups were compared at screening for age, sex, tin-
nitus location, duration and quality, mean hearing levels, tinnitus loudness and annoy-
ance and THQ scores, zinc and copper serum levels, and trial dropouts for potential
influences on treatment outcome. No differences across groups were observed
Interventions Cross-over study
Phase I
Intervention group: 50 mg elemental zinc for 16 weeks (n = 54)
Comparator group: placebo for 16 weeks (n = 55)
Washout: 4 weeks
Phase II
Intervention group: 50 mg elemental zinc for 16 weeks (n = 45)
Comparator group: placebo for 16 weeks (n = 46)
Outcomes Primary outcome: improvement of tinnitus measured by changes of 20 points or greater
on the Tinnitus Handicap Questionnaire (THQ)
Secondary outcome: change in tinnitus loudness (0 to 100 scale)
Funding sources The study was funded by the Tinnitus Research Initiative (TRI Grant RT 06 10)
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Coelho 2013 (Continued)
Declarations of interest The authors declared that they have no conflicts of interest in the research
Notes Participants lost to follow-up: 20/106 (18.9%) proportionally distributed between the
groups
Trials register: NCT00683644
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not de-
scribed
Allocation concealment (selection bias) Low risk External allocation (pharmacy depart-
ment)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The blinding of participants and personnel
was described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The blinding of outcome assessment was
described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses 20/106 (18.9%); ITT analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing based on comparison of the methods
and results sections
Other bias Low risk There was no evidence of other bias
Paaske 1991
Methods Allocation: randomised, placebo-controlled, double-blind clinical trial
Design: parallel-group
Participants Number: 50
Age: median 57 years, range 29 to 77
Gender: 65% men
Setting: single centre, audiological clinic
Eligibility criteria: patients with tinnitus to such a degree that they wanted some form
of treatment
Exclusion criteria: not described
Baseline characteristics: the duration of tinnitus varied from 3 months to 34 years
(median 5 years). 3 of the patients had suffered from tinnitus for less than 6 months. 42
(88%) suffered from constant and 6 (12%) from intermittent tinnitus. No significant
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Paaske 1991 (Continued)
difference in age between the 2 groups was found
Interventions Intervention group: 66 mg elemental zinc daily for 8 weeks (n = 25)
Comparator group: placebo for 16 weeks (n = 25)
Outcomes Primary outcome: severity of tinnitus measured on a scale of 0 to 10
Funding sources Not reported
Declarations of interest Not reported
Notes Participants lost to follow-up: 2/50 (4%)
Trials register: not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding methods not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding methods not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses 2/50 (4%)
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing based on comparison of the methods
and results sections
Other bias Low risk There was no evidence of other bias
ITT: intention-to-treat
THQ: Tinnitus Handicap Questionnaire
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gersdorff 1987 ALLOCATION
Not randomised
Ochi 1997 ALLOCATION
Not randomised
Ochi 2003 ALLOCATION
Not randomised
Person 2004 ALLOCATION
Not randomised
Person 2010 ALLOCATION
Not randomised
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D A T A A N D A N A L Y S E S
Comparison 1. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in tinnitus severity
and disability, measured by
a validated tinnitus-specific
questionnaire
1 187 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [0.50, 12.70]
2 Tinnitus loudness 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Mean dB 1 41 Mean Difference (IV, Fixed, 95% CI) -9.71 [-25.53, 6.11]
2.2 Scale 0 to 100 1 187 Mean Difference (IV, Fixed, 95% CI) 0.5 [-5.08, 6.08]
3 Mean overall severity of tinnitus:
scale 0 to 7
1 41 Mean Difference (IV, Fixed, 95% CI) -1.41 [-2.97, 0.15]
4 Improvement tinnitus severity 1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.17, 7.10]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have specified that we considered cross-over studies for inclusion in Types of studies.
We included in the Unit of analysis issues section: “For trials with a cross-over design, the data would have been included using the
results of paired analyses (Elbourne 2002)”.
We included the result of two studies that used a non-validated scale to measure the secondary outcome, change in overall severity of
tinnitus.
We have moved ’adverse effects’ from a secondary to a primary outcome measure.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tinnitus [∗therapy]; Treatment Outcome;
Zinc [administration & dosage; ∗therapeutic use]
MeSH check words
Adult; Aged; Humans; Middle Aged
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